FDA CDC News
FDA Authorizes Updated Novavax COVID-19 Vaccine for Variant Protection
FDA authorizes updated Novavax COVID-19 vaccine for better protection against circulating variant. Learn more.
The U.S. Food and Drug Administration (FDA) has authorized an updated version of the Novavax COVID-19 Vaccine to better protect against the currently circulating variant. The emergency use authorization now includes the 2023-2024 formula of the vaccine for individuals aged 12 and older. Previously vaccinated individuals who have not received an updated mRNA COVID-19 vaccine are eligible for a single dose, while unvaccinated individuals require two doses. This updated vaccine incorporates the spike protein from the SARS-CoV-2 omicron variant lineage XBB.1.5, providing improved protection against severe consequences of COVID-19. The FDA’s decision aligns with recent approvals of updated mRNA COVID-19 vaccines by Moderna and Pfizer. The Novavax COVID-19 Vaccine has met the FDA’s standards for safety, effectiveness, and manufacturing quality, making it a valuable option for individuals seeking better protection against currently circulating variants.